Prana Phase IIa Alzheimer's Disease Trial Continues
Posted on: Tuesday, 7 August 2007, 15:10 CDT
Prana Biotechnology has said that an independent data safety monitoring board has confirmed the safety of the company's Phase IIa trial of its early Alzheimer's disease treatment.
So far, the independent data safety monitoring board has reviewed blinded data of over 50 patients; there have been no treatment-related serious adverse events or withdrawals, and the trial has now been confirmed safe to continue as per the original protocol.
In total, 55 patients (or approximately 70% of the planned 80 patients) have been randomized, 30 patients have completed dosing, and as planned, patient dosing is expected to be completed by the end of 2007.
This Phase IIa trial is a double-blind, placebo-controlled safety and tolerability study of PBT2 in patients with mild forms of Alzheimer's disease. PBT2 is Prana's proprietary lead compound.
In addition, the trial is investigating the effect of PBT2 on multiple cerebrospinal fluid (CSF) and blood biomarkers that have been directly associated with the etiology of Alzheimer's disease. Outcomes will include measures of CSF A-beta and tau levels, as well as neurocognitive and behavioral changes.
Source: Datamonitor
Related Articles
- Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7
- Quantros Launches Patient Safety Organization Manager to Streamline PSO Data Management and Submission to the Network of Patient Safety Databases
- Sciele Pharma Completes Phase III Safety Trial for Glycopyrrolate Liquid, a Treatment for Chronic, Moderate-to-Severe Drooling in Pediatric Patients
- AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program With Cetrorelix in Benign Prostatic Hyperplasia
- Research and Markets: 2007 Trial TRAX - Alzheimer's Disease - Clinical Trial Monitoring Brief Provides Detailed Compilations And Analysis Of Ongoing Studies
- Sciele Pharma Completes Patient Enrollment for Pivotal Phase III Safety Trial for Glycopyrrolate
- Speedel Stops Current SPP301 Phase III Trial in Diabetic Kidney Disease in the Interests of Patient Safety; Data to Be Analysed for Potential New Clinical Trials
- In Interests of Patient Safety, Pfizer Stops All Torcetrapib Clinical Trials; Company Has Notified FDA and is in the Process of Notifying All Clinical Investigators and Other Regulatory Authorities
- Slow Progress in Boosting U.S. Patient Safety
- Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision
 |
 |
User Comments (0)
RSS Feeds